Treatment of Adult T-cell Leukemia-Lymphoma in the Aggressive Leukaemic Form

The aggressive leukaemic form of adult T-cell leukaemia/lymphoma (ATLL) represents a clinically urgent presentation requiring prompt, structured intervention. The approach differs meaningfully from other ATLL subtypes and follows specific evidence-based recommendations.

Clinical scenario Patients presenting with the aggressive leukaemic form of adult T-cell leukaemia/lymphoma. This subtype carries a high disease burden and requires a distinct first-line management strategy, including consideration of consolidative transplantation for eligible patients.

Treatment approach (partial summary)

First-line therapy centres on an antiviral-based combination regimen at high initial doses, with growth factor support, followed by a dose-reduction strategy in responding patients. Allogeneic haematopoietic stem cell transplantation is considered for all potentially eligible patients to consolidate response.

Full regimen details, sequencing, eligibility criteria, and alternative strategies are available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/bjh.17951

Patients with aggressive leukaemic form of ATLL should be offered high-dose AZT/IFN-a and non-responders should be switched to chemotherapy (GRADE 1C).
In the aggressive form of acute ATLL higher initial doses of AZT/IFN-a are used before reducing to maintenance dosing in responding patients.
G-CSF support is usually required.
All potentially eligible patients should be offered allo-HSCT to consolidate response (GRADE 1B).
For patients ineligible for allo-HSCT, consider maintenance therapy with AZT/IFN-a.
If AZT/IFN-a is poorly tolerated, consider oral low-dose etoposide-containing chemotherapy (GRADE 1C).
Consider addition of an integrase inhibitor (e.g. raltegravir) to transplant conditioning protocols to prevent neo-infection of donor stem cells (GRADE 2D).

View source ↗